Shots:
Amgen has acquired Dark Blue Therapeutics, strengthening its early oncology discovery efforts & pipeline
As per the deal, Amgen acquired Dark Blue Therapeutics in a transaction valued at ~$840M, integrating Dark Blue into its existing research organization
Acquisition will add a preclinical small molecule that degrades MLLT1/3 in select acute myeloid leukemia subtypes, showing differentiated anti-cancer activity…
